[PDF][PDF] The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia

L Klemm, C Duy, I Iacobucci, S Kuchen… - Cancer cell, 2009 - cell.com
L Klemm, C Duy, I Iacobucci, S Kuchen, G von Levetzow, N Feldhahn, N Henke, Z Li…
Cancer cell, 2009cell.com
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for
many years with Imatinib until leukemia cells acquire drug resistance through BCR-ABL1
mutations and progress into fatal B lymphoid blast crisis (LBC). Despite its clinical
significance, the mechanism of progression into LBC is unknown. Here, we show that LBC
but not CML cells express the B cell-specific mutator enzyme AID. We demonstrate that AID
expression in CML cells promotes overall genetic instability by hypermutation of tumor …
Summary
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years with Imatinib until leukemia cells acquire drug resistance through BCR-ABL1 mutations and progress into fatal B lymphoid blast crisis (LBC). Despite its clinical significance, the mechanism of progression into LBC is unknown. Here, we show that LBC but not CML cells express the B cell-specific mutator enzyme AID. We demonstrate that AID expression in CML cells promotes overall genetic instability by hypermutation of tumor suppressor and DNA repair genes. Importantly, our data uncover a causative role of AID activity in the acquisition of BCR-ABL1 mutations leading to Imatinib resistance, thus providing a rationale for the rapid development of drug resistance and blast crisis progression.
cell.com